NUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology Pipeline October 20, 2026
KymaThera Announces $80 Million Series B Financing to Advance K-1728, a Next-Gen Pan-Mutant Selective PI3Kα Inhibitor October 14, 2026
Prelude and Lilly to Evaluate PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer October 14, 2026
Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer October 14, 2026
SRX Global to Acquire CERo Therapeutics, a Company Developing CER 1236 for Hematologic Malignancies October 14, 2026
Tempus Announces Multi-Year Collaboration with Moderna and Merck, to Support Potential Commercialization of Intismeran Autogene October 14, 2026
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million October 6, 2026
AstraZeneca, Daiichi Sankyo, and Summit Therapeutics to evaluate Datroway + ivonescimab combo across multiple tumour types October 6, 2026
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences October 6, 2026
United Immunity Announces Master Clinical Supply Agreement with Roche to Evaluate UI-102 + Anti–PD-L1 Therapy in Advanced Solid Tumors October 6, 2026
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma October 6, 2026
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs October 6, 2026
Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology October 1, 2026
AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance ADC combination strategy in cancer October 1, 2026
Henlius and Amberstone Partner to Develop Next-Generation Conditionally Activated TCEs for Solid Tumours October 1, 2026
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines October 1, 2026
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015 October 1, 2026
$92.5M Series E Financing to Advance First-in-class Cyclin D1 Program CID-615 into Clinical Development Announced September 22, 2026
Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development September 22, 2026